News Roche's COPD candidate fails a phase 3 readout Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.
News After FDA says no, Bayer bags EU nod for twice-yearly Eylea Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.
News FDA probing deaths with DMD gene therapy Elevidys The FDA has launched a formal investigation into two liver failure-related deaths in patients treated with Duchenne gene therapy Elevidys.
News Roche's Hemlibra follow-up set for phase 3 in haemophilia A Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.
News DMD gene therapy Elevidys linked to new liver failure case Another death from liver failure has been seen with Roche and Sarepta's Duchenne muscular dystrophy therapy Elevidys, prompting a pause on treatment.
News Roche builds case for MS drug with two-year efficacy data Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.